(Adnkronos) - "Questa nuova terapia per affrontare la miastenia gravis generalizzata è molto importante. Grazie a ravulizumab migliorano rapidamente i sintomi della malattia e si riducono gli effetti collaterali rispetto alla terapia standard". Queste le parole di Renato Mantegazza, presidente dell’Associazione italiana miastenia e malattie immunodegenerative amici del Besta (Aim) durante l'incontro "Una nuova gestione della miastenia gravis generalizzata: approvato ravulizumab per il trattamento dei pazienti adulti" che si è tenuto a Milano.
Category
🗞
NewsTranscript
00:00The arrival of this new therapy is extremely important, the indications for use are those
00:12as an addition to normal therapy, but what happens is that it quickly improves the symptoms
00:22because they are the refractory patients to be the first line to be involved and above all
00:32then it allows to reduce in a very significant way the conventional therapies which are those
00:40that are more prone to side effects, in particular the steroid therapy.
00:48The impact is extremely important because the disease affects almost all the daily activities of the patient,
00:59in addition to the daily activities, that is, personal and home activities, it can also have a very significant impact at the work level.
01:10It is true that patients are often forced to leave work early and not only patients but also caregivers who must assist the patient.